I
197.58
8.91 (4.72%)
| Previous Close | 188.67 |
| Open | 186.54 |
| Volume | 1,129,395 |
| Avg. Volume (3M) | 908,949 |
| Market Cap | 15,366,216,704 |
| Price / Earnings (TTM) | 26.63 |
| Price / Earnings (Forward) | 13.70 |
| Price / Sales | 1.85 |
| Price / Book | 1.53 |
| 52 Weeks Range | |
| Earnings Date | 22 Oct 2025 |
| Profit Margin | 9.82% |
| Operating Margin (TTM) | 12.83% |
| Diluted EPS (TTM) | 9.71 |
| Quarterly Revenue Growth (YOY) | -4.80% |
| Quarterly Earnings Growth (YOY) | 24.50% |
| Total Debt/Equity (MRQ) | 37.12% |
| Current Ratio (MRQ) | 1.29 |
| Operating Cash Flow (TTM) | 1.16 B |
| Levered Free Cash Flow (TTM) | 901.28 M |
| Return on Assets (TTM) | 4.35% |
| Return on Equity (TTM) | 8.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | ICON plc | Bullish | Bearish |
AIStockmoo Score
-0.3
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 5.0 |
| Average | -0.25 |
|
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Value |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 92.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 222.00 (Truist Securities, 12.36%) | Hold |
| Median | 191.50 (-3.08%) | |
| Low | 175.00 (BMO Capital, -11.43%) | Hold |
| Average | 195.00 (-1.31%) | |
| Total | 4 Hold | |
| Avg. Price @ Call | 180.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 22 Jan 2026 | 183.00 (-7.38%) | Hold | 186.74 |
| Truist Securities | 08 Jan 2026 | 222.00 (12.36%) | Hold | 188.22 |
| Barclays | 15 Dec 2025 | 200.00 (1.22%) | Hold | 184.37 |
| BMO Capital | 13 Nov 2025 | 175.00 (-11.43%) | Hold | 163.45 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership |
| 09 Dec 2025 | Announcement | ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive |
| 02 Dec 2025 | Announcement | ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions |
| 12 Nov 2025 | Announcement | ICON plc to Present at the Jefferies London Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |